NIBR0213
NIBR-0213 is a potent, orally active and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. NIBR-0213 displays potent and comparable potency on human and rat S1P1 (IC50 of 2.0 nM and 2.3 nM, respectively) in GTPγ35S assays[1].
Product Specifications
CAS Number
[1233332-14-3]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
LPL Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/nibr0213.html
Purity
99.0
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : ≥ 25mg/mL
Smiles
ClC1=CC=C([C@@H](C)NC2=CC=CC(C3=CC(C)=C(C(N[C@@H](C)C(O)=O)=O)C(C)=C3)=C2)C=C1C
Molecular Formula
C27H29ClN2O3
Molecular Weight
464.98
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PRKG1, CT (cGMP-dependent Protein Kinase 1, cGK 1, cGK1, cGMP-dependent Protein Kinase I, cGKI, PRKG1B, PRKGR1A, PRKGR1B) (FITC) discontinued
Influenza A H1N1 (A/Michigan/45/2015) Nucleoprotein / NP Protein (His Tag)
